PHARM Stock Price, News & Analysis

Pharming Group (Nasdaq: PHAR) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference in New York, scheduled for September 8-10, 2025. CEO Fabrice Chouraqui will deliver a presentation on Monday, September 8 at 1:30pm EDT/19:30 CEST.

Investors can access the live webcast and replay through Pharming's website in the "Upcoming Events" and "News" sections. One-on-one meetings with management can be arranged through Investor Relations or H.C. Wainwright representatives.

Pharming Group (NASDAQ: PHAR) has appointed Kenneth Lynard as its new Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global leadership experience in the life sciences industry, with significant expertise in financial and operational transformation.

Lynard's most recent roles include CFO positions at Schoeller Allibert and Zentiva. Notably, during his five-year tenure at Gilead Sciences as Senior VP and CFO of Global Commercial Operations, R&D and Manufacturing, he helped triple the business following the Pharmasset acquisition. His appointment follows Pharming's strong first half 2025 results and aims to strengthen the company's financial leadership as it pursues its vision of becoming a leading global rare disease company.

Pharming Group (NASDAQ:PHAR) announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, USA. CEO Fabrice Chouraqui will deliver a presentation on Tuesday, August 12, 2025, at 12:00 PM EDT/18:00 CEST.

Investors interested in one-on-one meetings with Pharming's management team can arrange them through the company's Investor Relations team or their Canaccord Genuity representative.

Pharming Group (NASDAQ:PHARM) reported strong Q2 2025 financial results with total revenues increasing 26% to US$93.2 million. The growth was driven by RUCONEST® revenue rising 28% to US$80.4 million and Joenja® revenue growing 15% to US$12.8 million.

The company achieved an operating profit of US$10.8 million in Q2 2025, compared to a US$3.1 million loss in Q2 2024. Cash position strengthened to US$130.8 million, up from US$108.9 million in Q1 2025. Based on strong performance, Pharming raised its 2025 revenue guidance to US$335-350 million.

A significant study published in Cell suggests APDS prevalence may be up to 100 times higher than previously estimated, potentially expanding Joenja's addressable market. The company also submitted a new drug application for leniolisib in Japan and launched Joenja® in the UK with first patients on commercial therapy.

Pharming Group (NASDAQ:PHAR) has scheduled its second quarter and first half 2025 financial results announcement and business update for July 31, 2025. The company will host a conference call and webcast for analysts and investors at 13:30 CEST/07:30 EDT on the same day.

Participants interested in asking questions during the event must register for the conference call to receive dial-in information and a unique PIN. A webcast option is also available for those who wish to watch the presentation, with a replay to be made available on Pharming's website after the event.

Pharming Group (NASDAQ:PHAR) announced a webcast to discuss findings from a groundbreaking study published in Cell journal regarding the diagnosis of activated phosphoinositide 3-kinase delta syndrome (APDS). The research, led by Columbia University scientists, successfully identified over 100 new variants with evidence for PI3Kδ pathway hyperactivity.

The study analyzed more than 2,000 PIK3CD/PIK3R1 variants in human T-cell lines, addressing the challenge of variants of uncertain significance (VUS) in APDS diagnosis. Currently, there are over 1,300 known U.S. patients with VUS in PIK3CD and PIK3R1 genes. The findings suggest APDS may be more prevalent than previously estimated.

The webcast featuring Dr. Joshua Milner will take place on June 30, 2025, at 16:30 CEST / 10:30 EDT.

Pharming Group announced that all proposals were approved at its 2025 Annual General Meeting of Shareholders. Key highlights include the appointment of Dr. Elaine Sullivan, an experienced pharmaceutical and biotech industry leader, to the Board of Directors for a four-year term. The company also reelected Mrs. Jabine van der Meijs and Mr. Leonard Kruimer as Non-Executive Directors for four-year terms. Mrs. Deborah Jorn and Mr. Steven Baert did not seek re-election after serving six and four years respectively. Shareholders approved the reappointment of Deloitte Accountants B.V. as external auditor for 2025 and renewed authorizations for the Board to issue and repurchase shares.

Pharming Group N.V. (Euronext: PHARM/Nasdaq: PHAR) has announced its management's participation in two key investor conferences in June 2025. The company will attend the Jefferies Global Healthcare Conference in New York on June 4-5, where CEO Fabrice Chouraqui will participate in a Fireside Chat Q&A session on June 5 at 2:00 pm EDT/20:00 CEST. Additionally, Pharming will participate in the Portzamparc Mid & Small Caps Conference in Paris on June 18.

Investors can access the Jefferies conference presentation via live webcast and replay through Pharming's website. Those interested in one-on-one meetings with management can arrange them through Pharming's IR team or their Jefferies or Portzamparc representatives.

Pharming Group reported strong Q1 2025 financial results with total revenues increasing 42% to US$79.1 million. RUCONEST® revenue grew 49% to US$68.6 million, while Joenja® revenue rose 9% to US$10.5 million. The company achieved an adjusted operating profit of US$0.8 million, compared to a US$16.3 million loss in Q1 2024. Key developments include Joenja's launch in England and Wales, planned FDA filing for pediatrics in Q3 2025, and completion of the Abliva acquisition. Pharming raised its 2025 revenue guidance to US$325-340 million from US$315-335 million. The company announced CFO Jeroen Wakkerman's departure and reported significant progress in patient enrollment for RUCONEST® and Joenja®, with 102 patients on paid Joenja therapy in the U.S. by quarter-end.